CoreAge Rx and Hone Health publish commercial offers for sermorelin, but an offer is not a clinical-outcome study. This comparison separates what their pages advertise from the evidence needed to support a medical conclusion.

CoreAge Rx is our featured commercial partner. Its placement is disclosed and does not mean that it has stronger treatment evidence or better patient outcomes. We checked public sources on September 22, 2026, without enrolling in either service.

Keep this in mind

CoreAge Rx and Hone Health publish commercial offers for sermorelin, but an offer is not a clinical-outcome study. This comparison separates what their.

The price claims have conditions

The CoreAge Rx product page advertises a starting price of $99 monthly. The word “starting” needs to remain attached to that figure until an individual offer has been confirmed.

Hone's async-care explanation lists $175 monthly without membership and $130 monthly for members, excluding the membership charge. Its product and membership pages describe different care arrangements. Confirm which one applies before presenting a total.

These sources support descriptions of public pricing. They do not establish equal service packages, identical prescriptions, or a clinical advantage for the lower number. The full CoreAge review and Hone review explain the source boundaries.

Ask what kind of evidence supports each statement

StatementEvidence needed
This is the advertised priceCurrent provider offer with its conditions
This is my total costA quote for the actual selected care arrangement
This process includes a particular appointmentApplicable program description and confirmation
This treatment improves a health outcomeRelevant clinical results, with design and limitations examined

A provider can describe its process accurately without supplying comparative outcome evidence. A reviewer should not turn a clear explanation of enrollment into a finding that the treatment is more effective.

Read the study behind a benefit claim

The NIH's clinical-study guide explains why design matters. Check the actual intervention, people studied, measured outcome, and uncertainty. Ask whether the source is a completed results report or only a study registration.

Our guides to study registration and observational versus randomized evidence help organize that review. A citation's presence is a starting point for reading, not the end of the analysis.

Keep the regulatory question separate

The FDA explains that compounded drugs are not FDA-approved. Historical research, a physician's involvement, and a provider's reputation do not establish approval of the current compounded preparation.

We have not verified a clinical winner between these providers. The defensible comparison concerns their described offers and the questions an individual reader should resolve with the clinician and pharmacy before deciding about treatment.

The source notes

Sources & further reading

Provider pages document advertised offers, not independently proven outcomes. Historical references may concern different products or uses. Check the dated discussion in each article for the scope of our research; offers can change.

  1. CoreAge Rx product page
  2. Hone's async-care explanation
  3. NIH's clinical-study guide
  4. FDA explains that compounded drugs are not FDA-approved